Dexamethasone ophthalmic - InSite Vision

Drug Profile

Dexamethasone ophthalmic - InSite Vision

Alternative Names: Dexamethasone ophthalmic 0.1%; DexaSite; ISV-305

Latest Information Update: 13 Nov 2015

Price : $50

At a glance

  • Originator InSite Vision
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Blepharitis; Ocular inflammation

Most Recent Events

  • 22 Jun 2017 InSite Vision plans a phase III trial for Ocular inflammation and Pain (NCT03192137)
  • 15 Jun 2017 InSite Vision plans a phase III trial for Ocular inflammation (In adolescents, In adults, In the elderly) (NCT03192150)
  • 03 Nov 2015 InSite Vision became an indirect wholly owned subsidiary of Sun Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top